Understanding the Pathogenesis, Therapeutic Targets/Drug Action and Pharmacogenetics of Type 2 Diabetes: Is There a Future for Personalised Medicine?
Affiliations
- PMID: 32334506
- DOI: 10.2174/1871530320666200425202312
Abstract
Type 2 diabetes (T2D) is a chronic non-communicable disease that is of major health concern with a steadily rising prevalence across the globe. It is a metabolic disorder characterized by high blood glucose level either as a result of impaired insulin secretion and/or insulin action usually termed insulin resistance. This disease is influenced by lifestyle/feeding habit changes and genetic factors which causes physiological changes in glucose and lipid metabolism. As such, antidiabetic treatments have targeted specific enzymes, receptors, transport proteins, hormones, transcription factors etc. that are related to glucose metabolism, fat metabolism, insulin secretion and insulin signalization. Genetic variations due to mutations in certain target genes have been shown to influence the pathogenesis of T2D but also these polymorphisms have been observed to alter the therapeutic efficacy of drugs as well as their safety. Pharmacogenetic studies have been able to identify specific genetic variants of target genes that affect the metabolism, therapeutic response and adverse effects of antidiabetic drugs with the aim to translate the research findings to clinical practice. However, pharmacogenetic studies have not fully been able to identify distinct genetic markers that can serve as biomarkers for genetic screening, thus, limiting personalised medicine. As we advocate personalise medicine for the management of T2D in the future, pharmacogenetic studies should lay emphasis in addressing challenges of genetic screening and its translation to personalised therapy.
Keywords: Type 2 diabetes; antidiabetic drugs; genetic factor; personalized medicine.; pharmacogenetics; polymorphism.
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
Similar articles
- Current Progress in Pharmacogenetics of Second-Line Antidiabetic Medications: Towards Precision Medicine for Type 2 Diabetes.J Clin Med. 2019 Mar 21;8(3):393. doi: 10.3390/jcm8030393.PMID: 30901912 Free PMC article. Review.
- Individualized therapy for type 2 diabetes: clinical implications of pharmacogenetic data.Mol Diagn Ther. 2012 Oct;16(5):285-302. doi: 10.1007/s40291-012-0002-7.PMID: 23018631 Review.
- Clinical pharmacogenetics and potential application in personalized medicine.Curr Drug Metab. 2008 Oct;9(8):738-84. doi: 10.2174/138920008786049302.PMID: 18855611 Review.
- Oral antidiabetic agents: current role in type 2 diabetes mellitus.Drugs. 2005;65(3):385-411. doi: 10.2165/00003495-200565030-00005.PMID: 15669880 Review.
- Pharmacogenetic studies update in type 2 diabetes mellitus.World J Diabetes. 2016 Aug 10;7(15):302-15. doi: 10.4239/wjd.v7.i15.302.PMID: 27555891 Free PMC article. Review.
No hay comentarios:
Publicar un comentario